The role of osteopontin in neurodegenerative diseases

Journal of Alzheimer's Disease

Volumn 25, Issue 2, 2011, Pages 179-185

  Carecchio, Miryam ^a   Comi, Cristoforo ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Neurorehabilitation Institute ML Novarese   (Italy)

Author keywords

Alzheimer's disease; Eta 1; multiple sclerosis; Parkinson's disease; SPP1

Indexed keywords

OSTEOPONTIN;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; EXTRAPYRAMIDAL SYNDROME; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 79960720555     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-102151     Document Type: Review

References (54)

1. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19, 333-345.
2. Patarca R, Saavedra RA, Cantor H (1993) Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early Tlymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13, 225-246. (Pubitemid 2030713)
3. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H(2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 4, 60-64.
4. Murugaiyan G, Mittal A, Weiner HL (2008) Increased osteo-pontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol 181, 7480-7488.
5. Steinman L (2007) A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13, 139-145.
6. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107, 1055-1061. (Pubitemid 32422899)
7. Steinman L (2009) A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 9, 440-447.
8. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731-1735. (Pubitemid 33104847)
9. Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H (2002) Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168, 2096-2099. (Pubitemid 34171807)
10. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blaś Navarro J, Rio J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158, 231-239. (Pubitemid 39626091)
11. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, Polman CH, Nagelkerken L (2004) Osteopontin levels and increased disease activity in relapsing remitting multiple sclerosis patients. J Neuroimmunol 155, 155-160. (Pubitemid 39165788)
12. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L (2007) Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 8, 74-83. (Pubitemid 46242361)
13. Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, Castelli L, Bottarel F, Mazzarino MC, Garbarini L, Giacopelli F, Valesini G, Santoro C, Dianzani I, Ramenghi U, Dianzani U (2004) High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 103, 1376-1382. (Pubitemid 38168652)
14. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS (2001) Flexible structures of SIBLING proteins, bone sialo-protein, and osteopontin. Biochem Biophys Res Commun 280, 460-465. (Pubitemid 32912812)
15. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against a4ß1 integrin. Nature 356, 63-66.
16. Steinman L (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Rev Drug Discov 4, 510-519.
17. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K (2003) Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol 136, 125-129. (Pubitemid 36298851)
18. Caillier S, Barcellos LF, Baranzini SE, Swerdlin A, Lincoln RR, Steinman L, Martin E, Haines JL, Pericak-Vance M, Hauser SL, Oksenberg JR; Multiple Sclerosis Genetics Group (2003) Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun 4, 312-315. (Pubitemid 39562131)
19. Hensiek AE, Roxburgh R, Meranian M, Seaman S, Yeo T, Compston DA, Sawcer SJ (2003) Osteopontin gene and clinical severity of multiple sclerosis. J Neurol 250, 943-947. (Pubitemid 37041025)
20. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, Mazzarino MC, Giordano M, D'Alfonso S, Momigliano-Richiardi P, Liguori M, Zorzon M, Amoroso A, Trojano M, Monaco F, Leone M, Magnani C, Dianzani U (2005) Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 163, 172-178. (Pubitemid 40692960)
21. Steinman L, Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2003) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Comment in: Science 299, 1845.
22. Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, King JS, Stenzel-Poore MP (2008) Nasal administration of osteopontin peptide mimetics confers neuropro-tection in stroke. J Cereb Blood Flow Metab 28, 1235-1248. (Pubitemid 351733347)
23. Meller R, Stevens SL, Minami M, Cameron JA, King S, Rosenzweig H, Doyle K, Lessov NS, Simon RP, Stenzel-Poore MP (2005) Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 25, 217-225. (Pubitemid 40171203)
24. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20, 415-455.
25. Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221, 1082-1084. (Pubitemid 13041967)
26. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
27. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neu-ronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363. (Pubitemid 26111202)
28. McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326, 155-158. (Pubitemid 34722448)
29. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269. (Pubitemid 19140359)
30. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson's disease: i NOS, lipocortin-1, and cyclo-oxygenases-1 and -2. Mol Cell Neurosci 16, 724-739. (Pubitemid 32062060)
31. Rollo EE, Laskin DL, Denhardt DT (1996) Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol 60, 397-404. (Pubitemid 26325622)
32. Rollo EE, Denhardt DT (1996) Differential effects of osteo-pontin on the cytotoxic activity of macrophages from young and old mice. Immunology 88, 642-647. (Pubitemid 26255138)
33. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT (2002) Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85, 728-736. (Pubitemid 34464123)
34. Iczkiewicz J, Rose S, Jenner P (2004) Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res Mol Brain Res 132, 64-72. (Pubitemid 39531353)
35. Iczkiewicz J, Rose S, Jenner P (2005) Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur J Neurosci 21, 1911-1920. (Pubitemid 40685869)
36. Iczkiewicz J, Rose S, Jenner P (2007) Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Exp Neurol 207, 95-106. (Pubitemid 47332486)
37. Iczkiewicz J, Jackson MJ, Smith LA, Rose S, Jenner P (2006) Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease. Brain Res 1118, 239-250. (Pubitemid 44740248)
38. Hwang SM, Wilson PD, Laskin JD, Denhardt DT (1994) Age and development-related changes in osteopontin and nitric oxide synthase m RNA levels in human kidney proximal tubule epithelial cells: contrasting responses to hypoxia and reoxygenation. J Cell Physiol 160, 61-68. (Pubitemid 24214036)
39. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C (2007) Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis 25, 473-482.
40. Iczkiewicz J, Broom L, Cooper JD, Wong AM, Rose S, Jenner P (2010) The RGD-containing peptide fragment of osteopon-tin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem 114, 1792-1804.
41. Maetzler W, Michelis J, Tomiuk J, Melms A, Becker C, Gasser T, Schulte C, Berg D (2009) A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. J Neural Transm 116, 599-605.
42. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
43. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ (2006) The significance of neuroin-flammation in understanding Alzheimer's disease. J Neural Transm 113, 1685-1695. (Pubitemid 44657664)
44. Lee MY, Choi JS, Lim SW, Cha JH, Chun MH, Chung JW (2001) Expression of osteopontin m RNA in developing rat brainstem and cerebellum. Cell Tissue Res 6, 179-185.
45. Shin SL, Cha JH, Chun MH, Chung JW, Lee MY (1999) Expression of osteopontin m RNA in the adult rat brain. Neu-rosci Lett 273, 73-76.
46. Wung JK, Perry G, Kowalski A, Harris PL, Bishop GM, Trivedi MA, Johnson SC, Smith MA, Denhardt DT, Atwood CS (2007) Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Curr Alzheimer Res 4, 67-72. (Pubitemid 46293885)
47. Selvaraju R, Bernasconi L, Losberger C, Graber P, Kadi L, Avellana-Adalid V, Picard-Riera N, Van Evercooren AB, Cirillo R, Kosco-Vilbois M, Feger G, Papoian R, Boschert U (2004) Osteopontin is upregulated during in vivo demyeli-nation and remyelination and enhances myelin formation in vitro. Mol Cell Neurosci 25, 707-721. (Pubitemid 38481478)
48. Wirths O, Breyhan H, Marcello A, Cotel MC, Bruck W, Bayer TA (2008) Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neuro-biol Aging 31, 747-757.
49. Lin YH, Huang CJ, Chao JR, Chen ST, Lee SF, Yen JJ, Yang-Yen HF (2000) Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colonystimulating factor. Mol Cell Biol 20, 2734-2742. (Pubitemid 30183492)
50. Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K(2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64, 366-370. (Pubitemid 46425690)
51. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, Cappellano G, Monaco F, Scarpini E, Dianzani U (2010) Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis 19, 1143-1148.
52. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC (2010) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry, in press.
53. Mattsson N, Rüetschi U, Pijnenburg YA, Blankenstein MA, Podust VN, Li S, Fagerberg I, Rosengren L, Blennow K, Zetterberg H (2008) Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol Med Report 1, 757-761.
54. Burdo TH, Ellis RJ, Fox HS (2008) Osteopontin is increased in HIV-associated dementia, J Infect Dis 1, 715-722.